Ticker

The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 5,687,983 shares, a growth of 66.5% from the March 15th total of 3,416,161 shares. Approximately 11.7% of the shares of the stock are short sold. Based

Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $16.48, for a total value of $7,978,033.92. Following the completion of the transaction, the director owned 4,071,637 shares of

Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 135,201 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $16.59, for a total value of $2,242,984.59. Following the completion of the transaction, the director owned 3,936,436 shares in the

Vor Biopharma Inc. has pivoted to immunology, raising over $500m in 2025 to advance telitacicept for U.S. approval. VOR holds $530m cash, extending its runway into 2029, but faces significant dilution risk from outstanding warrants and equity plans. Telitacicept, already approved in China for multiple indications, must now clear pivotal Phase 3 US trials, with data not expected until 2027.